Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eptinezumab in chronic migraine
NCT04921384Phase 3Completed
- Sponsor
- Lundbeck
- Start
- May 2021
- Primary completion
- Oct 2024
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial of eptinezumab in chronic migraine (3 arms), sponsored by Lundbeck. Primary endpoint: Monthly Migraine Days at 12 weeks. Started May 2021; status: completed.
02
Drugs
eptinezumab
03
Conditions
chronic migraine
Beyond the preview
Go deeper on NCT04921384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04921384.